Shares of CareDx, Inc (NASDAQ:CDNA – Get Rating) saw unusually-high trading volume on Wednesday . Approximately 109,693 shares changed hands during mid-day trading, a decline of 87% from the previous session’s volume of 822,808 shares.The stock last traded at $17.07 and had previously closed at $16.92.
Analyst Upgrades and Downgrades
CDNA has been the topic of a number of recent research reports. StockNews.com raised shares of CareDx from a “sell” rating to a “hold” rating in a research note on Wednesday. BTIG Research reduced their price objective on shares of CareDx to $37.00 in a research note on Monday, August 15th. One analyst has rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $56.50.
CareDx Trading Down 1.8 %
The business’s 50-day moving average price is $21.39 and its two-hundred day moving average price is $26.43.
Insider Transactions at CareDx
In related news, Director Grace Colon sold 2,521 shares of the firm’s stock in a transaction on Wednesday, August 10th. The shares were sold at an average price of $24.81, for a total transaction of $62,546.01. Following the sale, the director now directly owns 4,864 shares in the company, valued at $120,675.84. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 4.60% of the company’s stock.
Institutional Investors Weigh In On CareDx
Several hedge funds and other institutional investors have recently added to or reduced their stakes in CDNA. Hardy Reed LLC bought a new position in shares of CareDx in the 1st quarter valued at about $41,000. Grandeur Peak Global Advisors LLC bought a new stake in shares of CareDx during the 1st quarter worth about $87,000. Lazard Asset Management LLC boosted its holdings in shares of CareDx by 32.0% during the 1st quarter. Lazard Asset Management LLC now owns 3,225 shares of the company’s stock worth $119,000 after buying an additional 782 shares during the period. Point72 Hong Kong Ltd bought a new stake in shares of CareDx during the 1st quarter worth about $131,000. Finally, Mesirow Financial Investment Management Inc. bought a new stake in shares of CareDx during the 1st quarter worth about $218,000.
CareDx, Inc discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.
- Get a free copy of the StockNews.com research report on CareDx (CDNA)
- The Institutions Hold On To Darden Restaurants International
- What Steelcase’s Earnings Say About the Return to the Office?
- Is The Golden Age Of Homebuilding Already Over?
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.